Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
John C ByrdPeter HillmenPaolo GhiaArnon P KaterAsher Chanan-KhanRichard R FurmanSusan O'BrienMustafa Nuri YenerelArpad IllésNeil E KayJose A Garcia-MarcoAnthony R MatoJavier Pinilla-IbarzJohn Francis SeymourStephane LepretreStephan StilgenbauerTadeusz RobakWayne RothbaumRaquel IzumiAhmed HamdyPriti PatelKara HigginsSophia SohoniWojciech JurczakPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
In this first direct comparison of less versus more selective Bruton's tyrosine kinase inhibitors in CLL, acalabrutinib demonstrated noninferior PFS with fewer cardiovascular adverse events.